Breast cancer in young women: Pathologic features and molecular phenotype
| Autor: | Sylvia Giard, Fabien Reyal, Pierre Azuar, Monique Cohen, Emile Daraï, Eric Lambaudie, Laura Sabiani, Jean Marc Classe, Charles Coutant, Christine Tunon de Lara, H. Charitansky, Nicolas Chopin, Richard Villet, Roman Rouzier, Jean Remy Garbay, Gilles Houvenaeghel, Mellie Heinemann, Pierre Gimbergues |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Molecular phenotype Breast Neoplasms Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Breast cancer Risk Factors Internal medicine medicine Adjuvant therapy Humans Neoplasm Metastasis Pathological Lymph node Proportional Hazards Models Retrospective Studies Gynecology Proportional hazards model business.industry Age Factors Retrospective cohort study General Medicine Middle Aged medicine.disease Prognosis 030104 developmental biology medicine.anatomical_structure Phenotype Chemotherapy Adjuvant 030220 oncology & carcinogenesis Surgery Female France Neoplasm Recurrence Local business Adjuvant |
| Zdroj: | Breast (Edinburgh, Scotland). 29 |
| ISSN: | 1532-3080 |
| Popis: | Controversy exists about the prognosis of breast cancer in young women. Our objective was to describe clinicopathological and prognostic features to improve adjuvant treatment indications.We conducted a retrospective multi centre study including fifteen French hospitals. Disease-free survival's data, clinical and pathological criteria were collected.5815 patients were included, 15.6% of them where between 35 and 40 years old and 8.7% below 35. In 94% of the cases, a palpable masse was found in patients ≤35 years old. Triple negative and HER2 tumors were predominantly found in patients ≤35 (22.2% and 22.1%, p 0.01). A young age ≤40 years (p 0.001; hazard ratio [HR]: 2.05; 95% confidence limit [CL]: 1.60-2.63) or ≤35 years (p 0.001; [HR]: 3.86; 95% [CL]: 2.69-5.53) impacted on the indication of chemotherapy. Age ≤35 (p 0.001; [HR]: 2.01; 95% [CL]: 1.36-2.95) was a significantly negative factor on disease-free survival. Chemotherapy (p 0.006; [HR]: 0.6; 95% [CL]: 0.40-0.86) and positive hormone receptor status (p 0.001; [HR]: 0.6; 95% [CL]: 0.54-0.79) appeared to be protector factors. Patients under 36, had a significantly higher rate of local recurrence and distant metastasis compared to patients35-40 (21.5 vs. 15.4% and 21.8 vs. 12.6%, p 0.01).Young women present a different distribution of molecular phenotypes with more luminal B and triple negative tumors with a higher grade and more lymph node involvement. A young age, must be taken as a pejorative prognostic factor and must play a part in indication of adjuvant therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect